nodes	percent_of_prediction	percent_of_DWPC	metapath
Carfilzomib—ABCB1—melanoma	0.324	1	CbGaD
Carfilzomib—PSMB2—skin epidermis—melanoma	0.012	0.121	CbGeAlD
Carfilzomib—PSMB5—hair follicle—melanoma	0.01	0.101	CbGeAlD
Carfilzomib—Death—Docetaxel—melanoma	0.0099	0.059	CcSEcCtD
Carfilzomib—PSMB1—hair follicle—melanoma	0.00876	0.0884	CbGeAlD
Carfilzomib—PSMB2—hair follicle—melanoma	0.00855	0.0863	CbGeAlD
Carfilzomib—Disease progression—Carmustine—melanoma	0.00813	0.0485	CcSEcCtD
Carfilzomib—Peripheral motor neuropathy—Docetaxel—melanoma	0.00625	0.0372	CcSEcCtD
Carfilzomib—Multi-organ failure—Dactinomycin—melanoma	0.00582	0.0347	CcSEcCtD
Carfilzomib—PSMB10—head—melanoma	0.00499	0.0503	CbGeAlD
Carfilzomib—PSMB8—mammalian vulva—melanoma	0.00449	0.0453	CbGeAlD
Carfilzomib—PSMB1—eye—melanoma	0.00437	0.0441	CbGeAlD
Carfilzomib—PSMB2—eye—melanoma	0.00427	0.0431	CbGeAlD
Carfilzomib—PSMB2—retina—melanoma	0.00423	0.0427	CbGeAlD
Carfilzomib—Haemorrhage intracranial—Temozolomide—melanoma	0.00418	0.0249	CcSEcCtD
Carfilzomib—PSMB5—mammalian vulva—melanoma	0.00397	0.0401	CbGeAlD
Carfilzomib—PSMB1—skin of body—melanoma	0.0038	0.0384	CbGeAlD
Carfilzomib—PSMB2—skin of body—melanoma	0.00371	0.0375	CbGeAlD
Carfilzomib—Multi-organ failure—Docetaxel—melanoma	0.0035	0.0209	CcSEcCtD
Carfilzomib—PSMB10—lymph node—melanoma	0.00349	0.0353	CbGeAlD
Carfilzomib—PSMB1—mammalian vulva—melanoma	0.00347	0.035	CbGeAlD
Carfilzomib—PSMB2—mammalian vulva—melanoma	0.00338	0.0342	CbGeAlD
Carfilzomib—Lymphopenia—Temozolomide—melanoma	0.00335	0.02	CcSEcCtD
Carfilzomib—Hypomagnesaemia—Bleomycin—melanoma	0.0032	0.0191	CcSEcCtD
Carfilzomib—PSMB1—head—melanoma	0.00248	0.025	CbGeAlD
Carfilzomib—Pain in extremity—Vemurafenib—melanoma	0.00244	0.0145	CcSEcCtD
Carfilzomib—PSMB2—head—melanoma	0.00242	0.0244	CbGeAlD
Carfilzomib—PSMB8—lymph node—melanoma	0.00225	0.0227	CbGeAlD
Carfilzomib—Lymphopenia—Docetaxel—melanoma	0.00223	0.0133	CcSEcCtD
Carfilzomib—PSMB5—lymph node—melanoma	0.00199	0.0201	CbGeAlD
Carfilzomib—Neuropathy peripheral—Vemurafenib—melanoma	0.00184	0.011	CcSEcCtD
Carfilzomib—PSMB1—lymph node—melanoma	0.00174	0.0175	CbGeAlD
Carfilzomib—PSMB2—lymph node—melanoma	0.0017	0.0171	CbGeAlD
Carfilzomib—Oedema peripheral—Vemurafenib—melanoma	0.00166	0.0099	CcSEcCtD
Carfilzomib—Sepsis—Dactinomycin—melanoma	0.00165	0.00981	CcSEcCtD
Carfilzomib—Cardiac disorder—Vemurafenib—melanoma	0.00157	0.00932	CcSEcCtD
Carfilzomib—Sepsis—Carmustine—melanoma	0.00154	0.00918	CcSEcCtD
Carfilzomib—Hepatic failure—Dactinomycin—melanoma	0.00153	0.00913	CcSEcCtD
Carfilzomib—Neuritis—Docetaxel—melanoma	0.00153	0.00911	CcSEcCtD
Carfilzomib—Chills—Vemurafenib—melanoma	0.00151	0.00901	CcSEcCtD
Carfilzomib—Back pain—Vemurafenib—melanoma	0.00142	0.00846	CcSEcCtD
Carfilzomib—Myocardial ischaemia—Docetaxel—melanoma	0.00142	0.00846	CcSEcCtD
Carfilzomib—Hepatic failure—Temozolomide—melanoma	0.00139	0.00826	CcSEcCtD
Carfilzomib—Hyponatraemia—Carmustine—melanoma	0.00129	0.00771	CcSEcCtD
Carfilzomib—Cough—Vemurafenib—melanoma	0.00128	0.00763	CcSEcCtD
Carfilzomib—Arthralgia—Vemurafenib—melanoma	0.00125	0.00745	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Dactinomycin—melanoma	0.00124	0.00739	CcSEcCtD
Carfilzomib—ABCB1—blood vessel—melanoma	0.00122	0.0124	CbGeAlD
Carfilzomib—Infection—Vemurafenib—melanoma	0.00119	0.00709	CcSEcCtD
Carfilzomib—Hypokalaemia—Carmustine—melanoma	0.00117	0.00699	CcSEcCtD
Carfilzomib—Pneumonia—Bleomycin—melanoma	0.00114	0.00682	CcSEcCtD
Carfilzomib—Hypokalaemia—Temozolomide—melanoma	0.00113	0.00675	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Bleomycin—melanoma	0.00112	0.00668	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Temozolomide—melanoma	0.00112	0.00668	CcSEcCtD
Carfilzomib—Neutropenia—Dactinomycin—melanoma	0.00111	0.00663	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Vemurafenib—melanoma	0.00109	0.0065	CcSEcCtD
Carfilzomib—Pneumonia—Dactinomycin—melanoma	0.00107	0.00636	CcSEcCtD
Carfilzomib—Neutropenia—Carmustine—melanoma	0.00104	0.00621	CcSEcCtD
Carfilzomib—Decreased appetite—Vemurafenib—melanoma	0.00104	0.0062	CcSEcCtD
Carfilzomib—Fatigue—Vemurafenib—melanoma	0.00103	0.00615	CcSEcCtD
Carfilzomib—Constipation—Vemurafenib—melanoma	0.00102	0.0061	CcSEcCtD
Carfilzomib—Hypoaesthesia—Bleomycin—melanoma	0.00102	0.00606	CcSEcCtD
Carfilzomib—Neutropenia—Temozolomide—melanoma	0.00101	0.006	CcSEcCtD
Carfilzomib—Hyperglycaemia—Carmustine—melanoma	0.00101	0.00599	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Temozolomide—melanoma	0.001	0.00596	CcSEcCtD
Carfilzomib—Pneumonia—Carmustine—melanoma	0.000999	0.00595	CcSEcCtD
Carfilzomib—Sepsis—Docetaxel—melanoma	0.00099	0.0059	CcSEcCtD
Carfilzomib—Renal failure—Carmustine—melanoma	0.000977	0.00582	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Carmustine—melanoma	0.000974	0.0058	CcSEcCtD
Carfilzomib—Hyperglycaemia—Temozolomide—melanoma	0.000971	0.00579	CcSEcCtD
Carfilzomib—Pneumonia—Temozolomide—melanoma	0.000966	0.00575	CcSEcCtD
Carfilzomib—Body temperature increased—Vemurafenib—melanoma	0.000947	0.00564	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Temozolomide—melanoma	0.000941	0.00561	CcSEcCtD
Carfilzomib—Hepatic failure—Docetaxel—melanoma	0.000922	0.00549	CcSEcCtD
Carfilzomib—Chills—Bleomycin—melanoma	0.000917	0.00546	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Docetaxel—melanoma	0.000914	0.00544	CcSEcCtD
Carfilzomib—Hypoaesthesia—Carmustine—melanoma	0.000887	0.00529	CcSEcCtD
Carfilzomib—Oedema peripheral—Carmustine—melanoma	0.000879	0.00523	CcSEcCtD
Carfilzomib—Asthenia—Vemurafenib—melanoma	0.00086	0.00512	CcSEcCtD
Carfilzomib—Hypoaesthesia—Temozolomide—melanoma	0.000858	0.00511	CcSEcCtD
Carfilzomib—Chills—Dactinomycin—melanoma	0.000855	0.00509	CcSEcCtD
Carfilzomib—Oedema peripheral—Temozolomide—melanoma	0.000849	0.00506	CcSEcCtD
Carfilzomib—Hyponatraemia—Docetaxel—melanoma	0.000832	0.00496	CcSEcCtD
Carfilzomib—Pain in extremity—Docetaxel—melanoma	0.000828	0.00494	CcSEcCtD
Carfilzomib—Anaemia—Bleomycin—melanoma	0.000822	0.0049	CcSEcCtD
Carfilzomib—Diarrhoea—Vemurafenib—melanoma	0.00082	0.00488	CcSEcCtD
Carfilzomib—Cardiac disorder—Temozolomide—melanoma	0.0008	0.00477	CcSEcCtD
Carfilzomib—Leukopenia—Bleomycin—melanoma	0.000796	0.00474	CcSEcCtD
Carfilzomib—Dizziness—Vemurafenib—melanoma	0.000792	0.00472	CcSEcCtD
Carfilzomib—Cough—Bleomycin—melanoma	0.000776	0.00462	CcSEcCtD
Carfilzomib—Chills—Temozolomide—melanoma	0.000773	0.00461	CcSEcCtD
Carfilzomib—Anaemia—Dactinomycin—melanoma	0.000767	0.00457	CcSEcCtD
Carfilzomib—Vomiting—Vemurafenib—melanoma	0.000762	0.00454	CcSEcCtD
Carfilzomib—Back pain—Carmustine—melanoma	0.000751	0.00447	CcSEcCtD
Carfilzomib—Headache—Vemurafenib—melanoma	0.000751	0.00447	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Docetaxel—melanoma	0.000746	0.00444	CcSEcCtD
Carfilzomib—Leukopenia—Dactinomycin—melanoma	0.000743	0.00442	CcSEcCtD
Carfilzomib—Back pain—Temozolomide—melanoma	0.000726	0.00432	CcSEcCtD
Carfilzomib—Infection—Bleomycin—melanoma	0.000721	0.0043	CcSEcCtD
Carfilzomib—Anaemia—Carmustine—melanoma	0.000718	0.00427	CcSEcCtD
Carfilzomib—Nausea—Vemurafenib—melanoma	0.000712	0.00424	CcSEcCtD
Carfilzomib—Thrombocytopenia—Bleomycin—melanoma	0.000711	0.00423	CcSEcCtD
Carfilzomib—Leukopenia—Carmustine—melanoma	0.000695	0.00414	CcSEcCtD
Carfilzomib—Anaemia—Temozolomide—melanoma	0.000693	0.00413	CcSEcCtD
Carfilzomib—Anorexia—Bleomycin—melanoma	0.000692	0.00412	CcSEcCtD
Carfilzomib—Infection—Dactinomycin—melanoma	0.000673	0.00401	CcSEcCtD
Carfilzomib—Leukopenia—Temozolomide—melanoma	0.000672	0.004	CcSEcCtD
Carfilzomib—Hypertension—Carmustine—melanoma	0.00067	0.00399	CcSEcCtD
Carfilzomib—Neutropenia—Docetaxel—melanoma	0.00067	0.00399	CcSEcCtD
Carfilzomib—Thrombocytopenia—Dactinomycin—melanoma	0.000663	0.00395	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Bleomycin—melanoma	0.000661	0.00394	CcSEcCtD
Carfilzomib—Cough—Temozolomide—melanoma	0.000655	0.0039	CcSEcCtD
Carfilzomib—Hypertension—Temozolomide—melanoma	0.000648	0.00386	CcSEcCtD
Carfilzomib—Dyspnoea—Bleomycin—melanoma	0.000647	0.00386	CcSEcCtD
Carfilzomib—ABCB1—retina—melanoma	0.000646	0.00652	CbGeAlD
Carfilzomib—Anorexia—Dactinomycin—melanoma	0.000645	0.00384	CcSEcCtD
Carfilzomib—Pneumonia—Docetaxel—melanoma	0.000642	0.00383	CcSEcCtD
Carfilzomib—Arthralgia—Temozolomide—melanoma	0.000639	0.00381	CcSEcCtD
Carfilzomib—Decreased appetite—Bleomycin—melanoma	0.000631	0.00376	CcSEcCtD
Carfilzomib—Infection—Carmustine—melanoma	0.000629	0.00375	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Docetaxel—melanoma	0.000629	0.00375	CcSEcCtD
Carfilzomib—Renal failure—Docetaxel—melanoma	0.000628	0.00374	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Docetaxel—melanoma	0.000626	0.00373	CcSEcCtD
Carfilzomib—Pain—Bleomycin—melanoma	0.000621	0.0037	CcSEcCtD
Carfilzomib—Thrombocytopenia—Carmustine—melanoma	0.00062	0.0037	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000617	0.00367	CcSEcCtD
Carfilzomib—Infection—Temozolomide—melanoma	0.000608	0.00362	CcSEcCtD
Carfilzomib—Anorexia—Carmustine—melanoma	0.000604	0.0036	CcSEcCtD
Carfilzomib—Thrombocytopenia—Temozolomide—melanoma	0.0006	0.00357	CcSEcCtD
Carfilzomib—Decreased appetite—Dactinomycin—melanoma	0.000588	0.00351	CcSEcCtD
Carfilzomib—Fatigue—Dactinomycin—melanoma	0.000584	0.00348	CcSEcCtD
Carfilzomib—Anorexia—Temozolomide—melanoma	0.000584	0.00348	CcSEcCtD
Carfilzomib—Pain—Dactinomycin—melanoma	0.000579	0.00345	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Carmustine—melanoma	0.000577	0.00344	CcSEcCtD
Carfilzomib—Body temperature increased—Bleomycin—melanoma	0.000574	0.00342	CcSEcCtD
Carfilzomib—Insomnia—Carmustine—melanoma	0.000573	0.00341	CcSEcCtD
Carfilzomib—Hypoaesthesia—Docetaxel—melanoma	0.00057	0.0034	CcSEcCtD
Carfilzomib—Dyspnoea—Carmustine—melanoma	0.000565	0.00337	CcSEcCtD
Carfilzomib—Oedema peripheral—Docetaxel—melanoma	0.000565	0.00336	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Temozolomide—melanoma	0.000558	0.00332	CcSEcCtD
Carfilzomib—Insomnia—Temozolomide—melanoma	0.000554	0.0033	CcSEcCtD
Carfilzomib—Decreased appetite—Carmustine—melanoma	0.000551	0.00328	CcSEcCtD
Carfilzomib—Dyspnoea—Temozolomide—melanoma	0.000546	0.00325	CcSEcCtD
Carfilzomib—Constipation—Carmustine—melanoma	0.000542	0.00323	CcSEcCtD
Carfilzomib—Pain—Carmustine—melanoma	0.000542	0.00323	CcSEcCtD
Carfilzomib—Body temperature increased—Dactinomycin—melanoma	0.000535	0.00319	CcSEcCtD
Carfilzomib—Decreased appetite—Temozolomide—melanoma	0.000532	0.00317	CcSEcCtD
Carfilzomib—Cardiac disorder—Docetaxel—melanoma	0.000532	0.00317	CcSEcCtD
Carfilzomib—Fatigue—Temozolomide—melanoma	0.000528	0.00315	CcSEcCtD
Carfilzomib—Constipation—Temozolomide—melanoma	0.000524	0.00312	CcSEcCtD
Carfilzomib—Pain—Temozolomide—melanoma	0.000524	0.00312	CcSEcCtD
Carfilzomib—Asthenia—Bleomycin—melanoma	0.000521	0.0031	CcSEcCtD
Carfilzomib—ABCB1—mammalian vulva—melanoma	0.000517	0.00522	CbGeAlD
Carfilzomib—Chills—Docetaxel—melanoma	0.000514	0.00306	CcSEcCtD
Carfilzomib—Body temperature increased—Carmustine—melanoma	0.000501	0.00298	CcSEcCtD
Carfilzomib—Asthenia—Dactinomycin—melanoma	0.000486	0.00289	CcSEcCtD
Carfilzomib—Body temperature increased—Temozolomide—melanoma	0.000484	0.00288	CcSEcCtD
Carfilzomib—Back pain—Docetaxel—melanoma	0.000483	0.00288	CcSEcCtD
Carfilzomib—Muscle spasms—Docetaxel—melanoma	0.00048	0.00286	CcSEcCtD
Carfilzomib—Diarrhoea—Dactinomycin—melanoma	0.000463	0.00276	CcSEcCtD
Carfilzomib—Vomiting—Bleomycin—melanoma	0.000462	0.00275	CcSEcCtD
Carfilzomib—Anaemia—Docetaxel—melanoma	0.000461	0.00275	CcSEcCtD
Carfilzomib—Asthenia—Carmustine—melanoma	0.000455	0.00271	CcSEcCtD
Carfilzomib—Leukopenia—Docetaxel—melanoma	0.000447	0.00266	CcSEcCtD
Carfilzomib—Asthenia—Temozolomide—melanoma	0.000439	0.00262	CcSEcCtD
Carfilzomib—Cough—Docetaxel—melanoma	0.000435	0.00259	CcSEcCtD
Carfilzomib—Diarrhoea—Carmustine—melanoma	0.000434	0.00258	CcSEcCtD
Carfilzomib—Nausea—Bleomycin—melanoma	0.000431	0.00257	CcSEcCtD
Carfilzomib—Hypertension—Docetaxel—melanoma	0.000431	0.00257	CcSEcCtD
Carfilzomib—Vomiting—Dactinomycin—melanoma	0.00043	0.00256	CcSEcCtD
Carfilzomib—Arthralgia—Docetaxel—melanoma	0.000425	0.00253	CcSEcCtD
Carfilzomib—Dizziness—Carmustine—melanoma	0.000419	0.0025	CcSEcCtD
Carfilzomib—Diarrhoea—Temozolomide—melanoma	0.000419	0.0025	CcSEcCtD
Carfilzomib—Dizziness—Temozolomide—melanoma	0.000405	0.00241	CcSEcCtD
Carfilzomib—Infection—Docetaxel—melanoma	0.000405	0.00241	CcSEcCtD
Carfilzomib—Vomiting—Carmustine—melanoma	0.000403	0.0024	CcSEcCtD
Carfilzomib—Nausea—Dactinomycin—melanoma	0.000402	0.0024	CcSEcCtD
Carfilzomib—Thrombocytopenia—Docetaxel—melanoma	0.000399	0.00238	CcSEcCtD
Carfilzomib—Headache—Carmustine—melanoma	0.000397	0.00236	CcSEcCtD
Carfilzomib—Vomiting—Temozolomide—melanoma	0.000389	0.00232	CcSEcCtD
Carfilzomib—Anorexia—Docetaxel—melanoma	0.000388	0.00231	CcSEcCtD
Carfilzomib—Headache—Temozolomide—melanoma	0.000384	0.00229	CcSEcCtD
Carfilzomib—Nausea—Carmustine—melanoma	0.000376	0.00224	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Docetaxel—melanoma	0.000371	0.00221	CcSEcCtD
Carfilzomib—ABCB1—head—melanoma	0.00037	0.00373	CbGeAlD
Carfilzomib—Insomnia—Docetaxel—melanoma	0.000368	0.00219	CcSEcCtD
Carfilzomib—Nausea—Temozolomide—melanoma	0.000364	0.00217	CcSEcCtD
Carfilzomib—Dyspnoea—Docetaxel—melanoma	0.000363	0.00216	CcSEcCtD
Carfilzomib—Decreased appetite—Docetaxel—melanoma	0.000354	0.00211	CcSEcCtD
Carfilzomib—Fatigue—Docetaxel—melanoma	0.000351	0.00209	CcSEcCtD
Carfilzomib—Pain—Docetaxel—melanoma	0.000348	0.00207	CcSEcCtD
Carfilzomib—Constipation—Docetaxel—melanoma	0.000348	0.00207	CcSEcCtD
Carfilzomib—Body temperature increased—Docetaxel—melanoma	0.000322	0.00192	CcSEcCtD
Carfilzomib—Lopinavir—ABCB1—melanoma	0.000312	0.543	CrCbGaD
Carfilzomib—Asthenia—Docetaxel—melanoma	0.000292	0.00174	CcSEcCtD
Carfilzomib—Diarrhoea—Docetaxel—melanoma	0.000279	0.00166	CcSEcCtD
Carfilzomib—Dizziness—Docetaxel—melanoma	0.000269	0.0016	CcSEcCtD
Carfilzomib—Ritonavir—ABCB1—melanoma	0.000262	0.457	CrCbGaD
Carfilzomib—ABCB1—lymph node—melanoma	0.000259	0.00261	CbGeAlD
Carfilzomib—Vomiting—Docetaxel—melanoma	0.000259	0.00154	CcSEcCtD
Carfilzomib—Headache—Docetaxel—melanoma	0.000255	0.00152	CcSEcCtD
Carfilzomib—Nausea—Docetaxel—melanoma	0.000242	0.00144	CcSEcCtD
Carfilzomib—PSMB9—Immune System—IL6—melanoma	1.07e-05	2.61e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—VCAN—melanoma	1.06e-05	2.59e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—MYC—melanoma	1.06e-05	2.59e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—STAT3—melanoma	1.06e-05	2.59e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—MAPK1—melanoma	1.06e-05	2.58e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—MAPK1—melanoma	1.06e-05	2.58e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—MAPK1—melanoma	1.06e-05	2.58e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—EGFR—melanoma	1.06e-05	2.58e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—EGFR—melanoma	1.06e-05	2.58e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—EGFR—melanoma	1.06e-05	2.58e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—NRAS—melanoma	1.06e-05	2.58e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—FGF2—melanoma	1.05e-05	2.58e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—MAPK1—melanoma	1.04e-05	2.55e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—EGFR—melanoma	1.04e-05	2.55e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—HRAS—melanoma	1.03e-05	2.53e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—HRAS—melanoma	1.03e-05	2.52e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—MAPK3—melanoma	1.03e-05	2.51e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—MAPK3—melanoma	1.03e-05	2.51e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—MAPK3—melanoma	1.03e-05	2.51e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—MAPK3—melanoma	1.01e-05	2.47e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—PTEN—melanoma	1.01e-05	2.46e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—PTEN—melanoma	1.01e-05	2.46e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—PTEN—melanoma	1.01e-05	2.46e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—VEGFA—melanoma	1e-05	2.45e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MDM2—melanoma	1e-05	2.44e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MDM2—melanoma	1e-05	2.44e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MDM2—melanoma	1e-05	2.44e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—KRAS—melanoma	9.98e-06	2.44e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—KRAS—melanoma	9.98e-06	2.44e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—KRAS—melanoma	9.98e-06	2.44e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—MYC—melanoma	9.97e-06	2.44e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—MYC—melanoma	9.97e-06	2.44e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—MYC—melanoma	9.97e-06	2.44e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—VEGFA—melanoma	9.97e-06	2.44e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—STAT3—melanoma	9.92e-06	2.43e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—PTEN—melanoma	9.91e-06	2.42e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—NRAS—melanoma	9.89e-06	2.42e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—IL6—melanoma	9.89e-06	2.42e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—AKT1—melanoma	9.88e-06	2.42e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—STAT3—melanoma	9.87e-06	2.41e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—ERBB2—melanoma	9.85e-06	2.41e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—ERBB2—melanoma	9.85e-06	2.41e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—ERBB2—melanoma	9.85e-06	2.41e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MDM2—melanoma	9.85e-06	2.41e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—NRAS—melanoma	9.85e-06	2.41e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—IL6—melanoma	9.84e-06	2.41e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—KRAS—melanoma	9.84e-06	2.41e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—AKT1—melanoma	9.84e-06	2.41e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—MYC—melanoma	9.83e-06	2.4e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Gene Expression—AKT1—melanoma	9.83e-06	2.4e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Gene Expression—AKT1—melanoma	9.78e-06	2.39e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—MAPK1—melanoma	9.76e-06	2.39e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—MAPK1—melanoma	9.76e-06	2.39e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—MAPK1—melanoma	9.76e-06	2.39e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—EGFR—melanoma	9.75e-06	2.39e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—EGFR—melanoma	9.75e-06	2.39e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—EGFR—melanoma	9.75e-06	2.39e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PIK3CB—melanoma	9.73e-06	2.38e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PIK3CB—melanoma	9.73e-06	2.38e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PIK3CB—melanoma	9.73e-06	2.38e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—ERBB2—melanoma	9.72e-06	2.38e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—MAPK1—melanoma	9.62e-06	2.35e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—EGFR—melanoma	9.62e-06	2.35e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PIK3CB—melanoma	9.59e-06	2.34e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MAPK3—melanoma	9.47e-06	2.32e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MAPK3—melanoma	9.43e-06	2.31e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—PIK3CA—melanoma	9.36e-06	2.29e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CXCL8—melanoma	9.35e-06	2.29e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CXCL8—melanoma	9.35e-06	2.29e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CXCL8—melanoma	9.35e-06	2.29e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—PIK3CA—melanoma	9.31e-06	2.28e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MYC—melanoma	9.22e-06	2.25e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—KRAS—melanoma	9.21e-06	2.25e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—KRAS—melanoma	9.21e-06	2.25e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—KRAS—melanoma	9.21e-06	2.25e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CXCL8—melanoma	9.21e-06	2.25e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MYC—melanoma	9.17e-06	2.24e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—PIK3CA—melanoma	9.17e-06	2.24e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—PIK3CA—melanoma	9.17e-06	2.24e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—PIK3CA—melanoma	9.17e-06	2.24e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—melanoma	9.16e-06	2.24e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CDKN1B—melanoma	9.13e-06	2.23e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CDKN1B—melanoma	9.13e-06	2.23e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CDKN1B—melanoma	9.13e-06	2.23e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—AKT1—melanoma	9.13e-06	2.23e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—KRAS—melanoma	9.09e-06	2.22e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—AKT1—melanoma	9.08e-06	2.22e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—PIK3CA—melanoma	9.04e-06	2.21e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MAPK1—melanoma	9.02e-06	2.2e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—EGFR—melanoma	9.01e-06	2.2e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CDKN1B—melanoma	9e-06	2.2e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MAPK1—melanoma	8.97e-06	2.19e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—EGFR—melanoma	8.97e-06	2.19e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CASP3—melanoma	8.94e-06	2.19e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CASP3—melanoma	8.94e-06	2.19e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CASP3—melanoma	8.94e-06	2.19e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP17A1—melanoma	8.94e-06	2.19e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IL2—melanoma	8.93e-06	2.18e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IL2—melanoma	8.93e-06	2.18e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IL2—melanoma	8.93e-06	2.18e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CASP3—melanoma	8.82e-06	2.16e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IL2—melanoma	8.81e-06	2.15e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CCND1—melanoma	8.71e-06	2.13e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CCND1—melanoma	8.71e-06	2.13e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CCND1—melanoma	8.71e-06	2.13e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CTNNB1—melanoma	8.62e-06	2.11e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CTNNB1—melanoma	8.62e-06	2.11e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CTNNB1—melanoma	8.62e-06	2.11e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CCND1—melanoma	8.58e-06	2.1e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—KRAS—melanoma	8.51e-06	2.08e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CTNNB1—melanoma	8.5e-06	2.08e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—HRAS—melanoma	8.48e-06	2.07e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—HRAS—melanoma	8.48e-06	2.07e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—HRAS—melanoma	8.48e-06	2.07e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—KRAS—melanoma	8.47e-06	2.07e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—PIK3CA—melanoma	8.47e-06	2.07e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—PIK3CA—melanoma	8.47e-06	2.07e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—PIK3CA—melanoma	8.47e-06	2.07e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MMP9—melanoma	8.45e-06	2.07e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MMP9—melanoma	8.45e-06	2.07e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MMP9—melanoma	8.45e-06	2.07e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GNA11—melanoma	8.44e-06	2.06e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CDKN1A—melanoma	8.42e-06	2.06e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CDKN1A—melanoma	8.42e-06	2.06e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CDKN1A—melanoma	8.42e-06	2.06e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PTEN—melanoma	8.4e-06	2.06e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PTEN—melanoma	8.4e-06	2.06e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PTEN—melanoma	8.4e-06	2.06e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—HRAS—melanoma	8.36e-06	2.05e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—NFKB1—melanoma	8.36e-06	2.05e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—NFKB1—melanoma	8.36e-06	2.05e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—NFKB1—melanoma	8.36e-06	2.05e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—PIK3CA—melanoma	8.35e-06	2.04e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MMP9—melanoma	8.33e-06	2.04e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CDKN1A—melanoma	8.3e-06	2.03e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PTEN—melanoma	8.29e-06	2.03e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—ALB—melanoma	8.27e-06	2.02e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—FASN—melanoma	8.26e-06	2.02e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—NFKB1—melanoma	8.25e-06	2.02e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—SLC5A5—melanoma	8.12e-06	1.99e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IL6—melanoma	8.12e-06	1.99e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IL6—melanoma	8.12e-06	1.99e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IL6—melanoma	8.12e-06	1.99e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IL6—melanoma	8.01e-06	1.96e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CD44—melanoma	7.85e-06	1.92e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GNAQ—melanoma	7.85e-06	1.92e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—HRAS—melanoma	7.83e-06	1.92e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—HRAS—melanoma	7.83e-06	1.92e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—HRAS—melanoma	7.83e-06	1.92e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—PIK3CA—melanoma	7.82e-06	1.91e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—PIK3CA—melanoma	7.79e-06	1.9e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—HRAS—melanoma	7.72e-06	1.89e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—AKT1—melanoma	7.64e-06	1.87e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—AKT1—melanoma	7.61e-06	1.86e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—VEGFA—melanoma	7.59e-06	1.86e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—VEGFA—melanoma	7.59e-06	1.86e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—VEGFA—melanoma	7.59e-06	1.86e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—TP53—melanoma	7.57e-06	1.85e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—TP53—melanoma	7.53e-06	1.84e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP1B1—melanoma	7.52e-06	1.84e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—STAT3—melanoma	7.52e-06	1.84e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—STAT3—melanoma	7.52e-06	1.84e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—STAT3—melanoma	7.52e-06	1.84e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—NRAS—melanoma	7.5e-06	1.83e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—NRAS—melanoma	7.5e-06	1.83e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—NRAS—melanoma	7.5e-06	1.83e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—IL6—melanoma	7.5e-06	1.83e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—IL6—melanoma	7.5e-06	1.83e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—IL6—melanoma	7.5e-06	1.83e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—AKT1—melanoma	7.49e-06	1.83e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—AKT1—melanoma	7.49e-06	1.83e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—AKT1—melanoma	7.49e-06	1.83e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—VEGFA—melanoma	7.48e-06	1.83e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—AKT1—melanoma	7.45e-06	1.82e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—AKT1—melanoma	7.45e-06	1.82e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—AKT1—melanoma	7.45e-06	1.82e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—STAT3—melanoma	7.41e-06	1.81e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—NRAS—melanoma	7.39e-06	1.81e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—IL6—melanoma	7.39e-06	1.81e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—AKT1—melanoma	7.39e-06	1.81e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—AKT1—melanoma	7.34e-06	1.8e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—HRAS—melanoma	7.24e-06	1.77e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—HRAS—melanoma	7.2e-06	1.76e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MAPK3—melanoma	7.18e-06	1.76e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MAPK3—melanoma	7.18e-06	1.76e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MAPK3—melanoma	7.18e-06	1.76e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—PIK3CA—melanoma	7.09e-06	1.73e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—PIK3CA—melanoma	7.09e-06	1.73e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—PIK3CA—melanoma	7.09e-06	1.73e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MAPK3—melanoma	7.08e-06	1.73e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—PIK3CA—melanoma	6.99e-06	1.71e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MYC—melanoma	6.98e-06	1.71e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MYC—melanoma	6.98e-06	1.71e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MYC—melanoma	6.98e-06	1.71e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—IL6—melanoma	6.93e-06	1.69e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—AKT1—melanoma	6.92e-06	1.69e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—AKT1—melanoma	6.92e-06	1.69e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—AKT1—melanoma	6.92e-06	1.69e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—IL6—melanoma	6.89e-06	1.69e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MYC—melanoma	6.89e-06	1.68e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MAPK1—melanoma	6.83e-06	1.67e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MAPK1—melanoma	6.83e-06	1.67e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MAPK1—melanoma	6.83e-06	1.67e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—EGFR—melanoma	6.83e-06	1.67e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—EGFR—melanoma	6.83e-06	1.67e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—EGFR—melanoma	6.83e-06	1.67e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—AKT1—melanoma	6.82e-06	1.67e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MAPK1—melanoma	6.74e-06	1.65e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—EGFR—melanoma	6.73e-06	1.65e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—KRAS—melanoma	6.45e-06	1.58e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—KRAS—melanoma	6.45e-06	1.58e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—KRAS—melanoma	6.45e-06	1.58e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—AKT1—melanoma	6.39e-06	1.56e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—KRAS—melanoma	6.36e-06	1.56e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—AKT1—melanoma	6.36e-06	1.56e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PIK3CA—melanoma	5.93e-06	1.45e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PIK3CA—melanoma	5.93e-06	1.45e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PIK3CA—melanoma	5.93e-06	1.45e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PIK3CA—melanoma	5.84e-06	1.43e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—AKT1—melanoma	5.79e-06	1.42e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—AKT1—melanoma	5.79e-06	1.42e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—AKT1—melanoma	5.79e-06	1.42e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—TP53—melanoma	5.74e-06	1.4e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—TP53—melanoma	5.74e-06	1.4e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—TP53—melanoma	5.74e-06	1.4e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—AKT1—melanoma	5.71e-06	1.4e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PRKCA—melanoma	5.7e-06	1.39e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—TP53—melanoma	5.65e-06	1.38e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ERCC2—melanoma	5.65e-06	1.38e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—HRAS—melanoma	5.49e-06	1.34e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—HRAS—melanoma	5.49e-06	1.34e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—HRAS—melanoma	5.49e-06	1.34e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—HRAS—melanoma	5.41e-06	1.32e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IL6—melanoma	5.25e-06	1.28e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IL6—melanoma	5.25e-06	1.28e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IL6—melanoma	5.25e-06	1.28e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IL6—melanoma	5.18e-06	1.27e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—AKT1—melanoma	4.84e-06	1.18e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—AKT1—melanoma	4.84e-06	1.18e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—AKT1—melanoma	4.84e-06	1.18e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—AKT1—melanoma	4.77e-06	1.17e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3CG—melanoma	4.47e-06	1.09e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PPARG—melanoma	4.31e-06	1.05e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3CD—melanoma	3.93e-06	9.6e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ALB—melanoma	3.88e-06	9.48e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3CB—melanoma	3.42e-06	8.37e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PTGS2—melanoma	3.39e-06	8.29e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PTEN—melanoma	2.96e-06	7.23e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3CA—melanoma	2.09e-06	5.1e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—AKT1—melanoma	1.7e-06	4.17e-06	CbGpPWpGaD
